# reload+after+2024-01-23 15:46:13.123829
address1§9119 Gaither Road
city§Gaithersburg
state§MD
zip§20877
country§United States
phone§301 825 9810
website§https://www.neximmune.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
fullTimeEmployees§22
companyOfficers§[{'maxAge': 1, 'name': 'Ms. Kristi  Jones R.Ph.', 'age': 60, 'title': 'CEO, President & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 680443, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mathias  Oelke Ph.D.', 'age': 54, 'title': 'Chief Scientific Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 621260, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Trainer M.B.A.', 'age': 49, 'title': 'Consultant', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 546134, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jerome Bernard Zeldis M.D., Ph.D.', 'age': 73, 'title': 'Consultant', 'yearBorn': 1950, 'fiscalYear': 2022, 'totalPay': 618199, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Timothy  Stover', 'title': 'VP, Corporate Controller and Principal Financial & Accounting Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Karen  Haslbeck', 'title': 'Head of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Daniel P. Bednarik', 'title': 'Senior Vice President of Molecular Engineering & Protein Design', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert Douglas Knight M.D.', 'age': 72, 'title': 'Chief Medical Officer', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 454771, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Chad  Rubin', 'title': 'Senior Vice President of Corporate Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jack A. Ragheb M.D., Ph.D.', 'title': 'Senior Vice President of Translational Science', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§7
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.752
currency§USD
dateShortInterest§1702598400
forwardEps§-3.75
exchange§NCM
quoteType§EQUITY
shortName§NexImmune, Inc.
longName§NexImmune, Inc.
firstTradeDateEpochUtc§1613140200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§eee25fcf-0d1b-3bd4-bd23-9a9f57c2d9b7
gmtOffSetMilliseconds§-18000000
recommendationMean§2.0
recommendationKey§buy
quickRatio§1.457
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
